ATAnouar Teriaky

Anouar Teriaky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anouar Teriaky has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A113 ANNUAL COLONOSCOPY VOLUME IS NOT PREDICTIVE OF COLONOSCOPY QUALITY - FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT

    by M Sey, O Siddiqi, C McDonald, S Cocco, Z Hindi, H Rahman, D Chakraborti, K French, M Alsager, M Blier, et al.

    Performing a minimum number of colonoscopies annually has been proposed by some jurisdictions as a requirement for maintaining privileges. However, this practice is supported by limited evidence. The objective of this study was to determine if annual colonoscopy volume was associated with colonoscopy quality metrics. A population-based study was performed using the Southwest Ontario Colonoscopy cohort, which consists of all adult patients who underwent colonoscopy between April 2017 and Oct 2018 at 21 academic and community hospitals within the health region. Data were collected through a mandatory quality assurance form completed after each procedure and pathology reports were manually reviewed. Physician annualized colonoscopy volumes were compared by correlation analysis to each quality-related outcome, by means of the area under the receiver operating characteristics curve (AUROC), and logistic regression. The prognostic value of colonoscopy volume was also adjusted for case-mix and potential confounders in separate regression analyses for each outcome. The primary outcome was ADR. Secondary outcomes were polyp detection rate (PDR), sessile serrated polyp detection rate (SSPDR), and cecal intubation. A total of 47,195 colonoscopies were performed by 75 physicians (37.5% by gastroenterologists, 60% by general surgeons, 2.5% others). There were no clear relationships between annual colonoscopy volumes and study outcomes. Colonoscopy volume was not associated with ADR (OR 1.03, 95% CI 0.96–1.10, p=0.48) and corresponded to an AUROC not significantly different from the null (AUROC 0.52, 95% CI 0.43–0.61, p=0.65). Multi-variable regression adjusting for case-mix also demonstrated no predictive value of annual colonoscopy volume for the primary outcome (OR 1.03, 95% CI 0.94–1.12, p=0.55). Similarly, analyses of secondary outcomes failed to find an association between colonoscopy volume and PDR, SSPDR, or cecal intubation (Table 1). Annual colonoscopy volumes do not predict ADR, PDR, SSPDR, or cecal intubation rate. Results of unconditional and conditional approaches for examining the predictive value of annual colonoscopy volume for quality related outcomes. None

  • Open Access

    A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE

    by S Al Draiweesh, C Ma, M Alkhattabi, C McDonald, N Chande, B G Feagan, J C Gregor, R Khanna, P Marotta, A S Sandhu, et al.

    Despite anti-rejection immunosuppressive therapies post-liver transplantation (LT), patients with concurrent inflammatory bowel disease (IBD) may have persistent bowel inflammation that requires addition of biologic therapy. To evaluate the safety of combination biologic and anti-rejection therapy in IBD patients after LT. The LT Registry at London Health Sciences Centre (LHSC) was searched to identify all patients undergoing LT from 1985–2018. IBD patients initiated on biologic treatment post-LT, in addition to anti-rejection therapy, were eligible for inclusion. Medical chart review was conducted to extract safety outcomes, including rates of infections, malignancy, colectomy and death. 19 patients were included (78.9% male, mean age 46.0 years, 8 patients with ulcerative colitis), followed for a median duration of 19 months (IQR 5.8, 30.8). Indications for LT included: primary sclerosing cholangitis (PSC) (14/19, 73.7%), autoimmune hepatitis (AIH) (2/19, 10.5%), AIH-PSC overlap syndrome (2/19, 10.5%), and biliary atresia (1/19, 5.3%). Post-LT, six patients were treated with only TNF antagonists (infliximab in 5 patients, golimumab in 1 patient); eight patients with only anti-integrin therapies (vedolizumab in 7 patients, natalizumab in 1 patient); and five patients with sequential TNF antagonists followed by either ustekinumab (n=2) or vedolizumab (n=3). Six patients required long-term prednisone. The most commonly used anti-rejection therapies were tacrolimus and mycophenolate mofetil. Disease course was complicated by infections in nine patients (47.4%), most commonly Clostridium difficile colitis (4/19, 31.6%). One patient had recurrent C. difficile infection and one patient had CMV colitis and viremia. Other infections included cholangitis (n=2), perianal abscess (n=1), JC virus seroconversion but without progressive multifocal leukoencephalopathy (n=1) and hospital-acquired pneumonia (n=1). Two patients required colectomy for refractory colitis. One patient required re-transplantation due to PSC recurrence. No deaths or malignancies were reported although one patient developed low grade colonic dysplasia. This is the largest reported case series from a single center to date evaluating the safety of combination biologic therapy with anti-rejection regimens in IBD patients post-LT. Whilst there appeared to be an increased risk of enteric infections, especially Clostridium difficile,there were no life-threatening infections reported. Active screening for enteric infections should be pursued in these patients presenting with increased IBD symptoms. None

  • Open Access

    A272 UTILIZING BEDSIDE ULTRASOUND TO ASSESS MUSCLE MASS IN CIRRHOTIC PATIENTS ASSESSED FOR LIVER TRANSPLANTATION

    by J Mandill, M Hilwah, L Sinclair, A Hussam Eddin, C Brown, M Anwar, A Teriaky, P Marotta, K Qumosani

    Muscle atrophy is present in 40% of cirrhotic patients and associated with increased morbidity and mortality in those awaiting liver transplantation (LT). There is a two-fold increase in mortality, compared to non-sarcopenic patients, independent of liver dysfunction using Model for End-Stage Liver Disease (MELD). The current Sodium MELD score does not incorporate markers of nutritional status, or muscle loss. Ultrasound is a non-invasive method to evaluate skeletal muscle and is validated and emerging as a prognostic indicator of muscle atrophy, thereby improving detection of malnutrition. To assess quadriceps muscle layer thickness (QMLT) using ultrasound across a range of nutritional risk scores: Royal Free Hospital Nutrition Prioritizing Tool (RFNS), illness severity scores: Sodium MELD and muscle strength: Hand-Grip Strength (HGS). A prospective study from July 2016 to May 2018 was conducted using QMLT measures in 93 adult patients assessed for LT. QMLT was measured at mid-point from anterior superior iliac spine (ASIS) and patella. These measures were compared to sodium MELD scores, RFNS, and HGS. Statistical analysis: Data were normally distributed, student t-test and Pearson correlations were performed, significance as P < .05, using SPSS. Twenty three percent of patients were diagnosed with NASH, 20% HCV, 20% ETOH, and 37% other liver diseases. 63% males, mean age (y) ± SEM: 58.6 ±1.35, BMI 28.4 ± 0.785; 37% females: 58.2 ± 2.33, BMI 24.1 ± 0.875, p=0.001. Mean QMLT [cm], males: 8.3 ± .642 versus females: 5.9 ± 0.60 p=0.008, HGS [kg]: 35.2 ± 1.53 versus females: 22.7 ± 2.17, p=0.001. Pearson correlation (males only): QMLT with Na-MELD r= -0.460 p=0.001; HGS r=0.423 p=0.002; RFNS: r= -0.592, p=0.001. Females showed associations between QMLT and HGS r=0.761 p=0.001 and RFNS r=-0.374 p=0.029. However, there were no correlations between QMLT, and NaMELD, edema or disease type in females. In both sexes QMLT was associated with HGS and RFNS indicating as muscle mass decreases, HGS and RFNS worsens. There was a negative association between QMLT and NaMELD in males, however, in females worsening QMLT was not associated with illness severity by NaMELD, indicating assessment of muscle mass differs by gender suggesting individualized nutritional therapies in potential LT recipients. Future studies are needed to determine the relationship, if any, with QMLT scores and morbidity and mortality. None


  • Open Access

    DOP39 Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience

    by S Al Draiweesh, C Ma, M Alkhattabi, N Chande, B G Feagan, J C Gregor, R Khanna, P Marotta, A Sandhu, K Qumosani, et al.

    Despite anti-rejection immunosuppressive therapies post-liver transplantation (LT), patients with concurrent inflammatory bowel disease (IBD) may have persistent bowel inflammation that requires addition of biologic therapy. The aim of this study was to evaluate the safety of combination biologic and anti-rejection therapy in IBD patients after LT. The LT Registry at London Health Sciences Centre (LHSC) was searched to identify all patients undergoing LT from 1985 to 2018. IBD patients initiated on biologic treatment post-LT, in addition to anti-rejection therapy, were eligible for inclusion. Medical chart review was conducted to extract safety outcomes, including rates of infections, malignancy, colectomy and death. Nineteen patients were included (78.9% male, mean age 46.0 years, 8 patients with ulcerative colitis), followed for a median duration of 19 months (IQR 5.8, 30.8). Indications for LT included: primary sclerosing cholangitis (PSC) (14/19, 73.7%), autoimmune hepatitis (AIH) (2/19, 10.5%), AIH-PSC overlap syndrome (2/19, 10.5%), and biliary atresia (1/19, 5.3%). Post-LT, six patients were treated with only TNF antagonists (infliximab in 5 patients, golimumab in 1 patient); eight patients with only anti-integrin therapies (vedolizumab in 7 patients, natalizumab in 1 patient); and five patients with sequential TNF antagonists followed by either ustekinumab (n = 2) or vedolizumab (n = 3). Six patients required long-term prednisone. The most commonly used anti-rejection therapies were tacrolimus and mycophenolate mofetil. Disease course was complicated by infections in nine patients (47.4%), most commonly Clostridium difficile colitis (4/19, 31.6%). One patient had recurrent C. difficile infection and one patient had CMV colitis and viremia. Other infections included cholangitis (n = 2), perianal abscess (n = 1), JC virus seroconversion but without progressive multifocal leukoencephalopathy (n = 1) and hospital-acquired pneumonia (n = 1). Two patients required colectomy for refractory colitis. One patient required re-transplantation due to PSC recurrence. No deaths or malignancies were reported although one patient developed low-grade colonic dysplasia. This is the largest reported case series from a single centre to date evaluating the safety of combination biologic therapy with anti-rejection regimens in IBD patients post-LT. Whilst there appeared to be an increased risk of enteric infections, especially C. difficile, there were no life-threatening infections reported. Active screening for enteric infections should be pursued in these patients presenting with increased IBD symptoms.

  • Open Access

    The Utility of Endoscopic Biopsies in Patients with Normal Upper Endoscopy

    by Anouar Teriaky, Abdullah AlNasser, Carolyn McLean, James Gregor, Brian Yan

    Background and Aims. Upper endoscopy is a valuable tool in the workup of gastrointestinal (GI) complaints. The purpose of this study is to determine cost and yield of taking biopsies in a normal upper GI tract.Methods. This is a retrospective study where all upper GI biopsies were identified between May 2012 and April 2013, at a tertiary care center. Clinical, procedural, and pathology reports were reviewed to identify patient demographics, procedure information, and pathology diagnosis.Results. Biopsies of the upper GI tract were taken in 1297 patients with normal upper endoscopies. In patients with normal upper endoscopy, 22% of esophageal, 44% of gastric, and 12% of duodenal biopsies were abnormal. The most frequent abnormality was reflux esophagitis in 16% of esophageal biopsies, chronic gastritis in 23% of gastric biopsies, and increased intraepithelial lymphocytes in 6% of duodenal biopsies. The additional cost for taking biopsies in a normal upper GI tract for a diagnosis of eosinophilic esophagitis was $2963 Canadian (CAD),H. pyloriassociated gastritis was $1404 CAD, and celiac disease was $3024 CAD.Conclusions. The yield of biopsy in normal upper endoscopy varied with location, but the additional expense can be costly and should be tailored to appropriate clinical situations.